SENIOR LEADERSHIP

高层领导

• 批准号: 8728345
• 负责人: JOSEPH Rocco BERTINO
• 金额: $ 3.13万
• 依托单位: RBHS -CANCER INSTITUTE OF NEW JERSEY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-07-01 至 2017-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8728345
• 关键词: Appointment; Basic Science; Cancer Center Support Grant; Cancer Institute of New Jersey; Clinical; Clinical Sciences; Comprehensive Cancer Center; Health Sciences; Human; Individual; Institutes; Instruction; Laboratories; Leadership; Medical Oncology; Mentorship; Mission; National Cancer Institute; New Brunswick; Population Sciences; Positioning Attribute; Prevention; Prostate; Public Health; Research; Resource Sharing; Services; Translational Research; Wages; programs

PROJECT SUMMARY (See instructions): Although senior leadership has been re-organized, the actual consistency and interactivity of the team remains stable. In fact, Dr. DiPaola was appointed as Director of CINJ following multiple appointments at CINJ including Co-Leader of the Prostate Program, Chief of Medical Oncology and Associate Director for Clinical Science. Dr. Edmund Lattime, a prior Associate Director, was appointed to the position of Deputy Director in 2008 by Dr. DiPaola. Dr. Joseph R. Bertino remains as Chief Scientific Officer. Dr. Michael Reiss continues as Associate Director for Translational Science and has appropriately assumed oversight of all basic science and translational shared resources. Dr. Eileen White, a Program Leader since 2004, was appointed Associate Director for Basic Science and, following a move of her laboratories to the main CINJ building in New Brunswick, increased basic science mentorship at CINJ. Dr. Joseph Aisner is Associate Director for Clinical Science as in the 2004 review, and Dr. Susan Goodin has been appointed Assistant Director for Clinical Science and Director ofthe Office of Human Research Services. Stability in administration also remains, as Ms. Linda Barker continues as Associate Director for Administration and Planning. As a new leader. Dr. Helmut Zarbl was appointed Associate Director for Public Health Science, overseeing CINJ's efforts in prevention, control, and population science. Salary support for these individuals is requested only for the effort attributable to research-related activities

项目摘要（请参阅说明）： 尽管高级领导层已经重组，但团队的实际一致性和互动性仍然稳定。实际上，Dipaola博士在CINJ任命后被任命为CINJ主任，包括前列腺计划的共同领导者，医学肿瘤学主任和临床科学副总监。先前的副主任埃德蒙·莱蒂姆（Edmund Lattime）博士于2008年被Dipaola博士任命为副主任。约瑟夫·贝蒂诺（Joseph R. Bertino）博士仍然是首席科学官。迈克尔·赖斯（Michael Reiss）博士继续担任转化科学副总监，并适当地探讨了所有基础科学和翻译共享资源。艾琳·怀特（Eileen White）博士自2004年以来一直是计划负责人，被任命为基础科学副主任，在将实验室搬到新不伦瑞克省的主要CINJ大楼之后，增加了CINJ的基础科学指导。 Joseph Aisner博士是2004年评论中的临床科学副总监，Susan Goodin博士被任命为临床科学助理主任和人类研究服务办公室主任。正如琳达·巴克（Linda Barker）女士继续担任行政和规划副主任一样，行政管理的稳定也保持不变。作为新的领导者。 Helmut Zarbl博士被任命为公共卫生科学副主任，负责CINJ在预防，控制和人口科学方面的努力。 仅要求对这些人的薪水支持，以归因于研究相关的活动的努力